Brown-Forman Corporation
BF-B
$24.87
-10.31%
Brown-Forman Corporation is a leading global producer and marketer of premium alcoholic beverages, operating in the Beverages - Wineries & Distilleries industry. The company is distinguished by its iconic portfolio, anchored by the Jack Daniel's Tennessee Whiskey brand, and is a dominant player in the American whiskey and premium spirits segments. The current investor narrative revolves around navigating a challenging macroeconomic environment for consumer staples, with recent attention focused on the company's ability to maintain growth and margins amidst inflationary pressures and shifting consumer demand, as evidenced by recent analyst rating actions and mixed quarterly performance.…
BF-B
Brown-Forman Corporation
$24.87
Investment Opinion: Should I buy BF-B Today?
Rating & Thesis: Hold. Brown-Forman is a high-quality, cash-generative business caught in a growth slowdown, making its current valuation fair but not compelling for new capital. The recent stabilization in analyst sentiment to Neutral aligns with this view.
Supporting Evidence: The stock trades at a forward P/E of 16.66x, which is reasonable but not a deep discount for its modest growth profile. Revenue growth is positive but tepid at 2.71% YoY. Profitability is a strength, with gross margins expanding to 60.87% and a robust ROE of 21.76%. The company's substantial $730M TTM free cash flow supports shareholder returns but does not fully offset the growth concerns embedded in its PS ratio of 4.14x.
Risks & Conditions: The two biggest risks are sustained low-single-digit revenue growth and further multiple compression from current levels. This Hold would upgrade to a Buy if the forward P/E compressed below 15x without a deterioration in margins, or if quarterly revenue growth sustainably reaccelerated above 5%. It would downgrade to a Sell if revenue growth turned negative or if margins began to contract sequentially. Relative to its own history and growth trajectory, the stock is fairly valued, not clearly overvalued or undervalued.
Sign up to view all
BF-B 12-Month Price Forecast
The outlook for BF-B is one of stability over excitement. The company's superb profitability and cash flow generation are offset by uninspiring top-line growth, leading to a neutral stance. The base case of sideways trading with modest upside is most probable. Confidence is medium because the key variable—revenue growth—has low visibility. The stance would upgrade to bullish on evidence of sustainable revenue acceleration above 5%, or downgrade to bearish if margins begin to contract or revenue growth turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Brown-Forman Corporation's 12-month outlook, with a consensus price target around $32.33 and implied upside of +30.0% versus the current price.
Average Target
$32.33
16 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
16
covering this stock
Price Range
$20 - $32
Analyst target range
The stock is covered by 16 analysts, indicating substantial institutional interest. The consensus recommendation and average target price are not explicitly provided in the data, but the institutional ratings show a recent shift towards neutrality, with Citigroup and JP Morgan upgrading from Sell/Underweight to Neutral in late March 2026. The absence of a stated consensus price target limits the calculation of implied upside/downside, but the recent rating actions suggest analyst sentiment may be stabilizing from previously bearish levels. The target range is also not provided in the dataset. The pattern of recent institutional ratings shows a notable cluster of actions in March 2026, with several firms moving to or reiterating Neutral/In-Line ratings, while Barclays maintains an Overweight. This suggests analysts are taking a wait-and-see approach following the stock's significant decline, with the high target likely banking on a brand-led recovery and the low target reflecting concerns over sustained top-line pressure.
Bulls vs Bears: BF-B Investment Factors
The evidence is currently balanced but tilts slightly bearish due to the persistent top-line weakness and severe technical damage. The bull case rests on strong profitability, cash generation, and a valuation that has normalized from historical extremes. The bear case highlights anemic growth, high absolute valuation multiples, and a stock still in a long-term downtrend. The single most important tension is whether the company's impressive margin expansion and cash flow can sustainably offset its lackluster revenue growth to justify its current valuation multiples. If revenue reaccelerates, the stock could rerate higher; if growth remains stagnant, the valuation remains vulnerable to further compression.
Bullish
- Strong Margin Recovery: Gross margins have improved sequentially from 57.38% in Q4 FY2025 to 60.87% in Q3 FY2026, demonstrating effective cost management and pricing power. This expansion is occurring despite modest revenue growth, indicating a strengthening profitability profile.
- Robust Cash Generation & Returns: The company generates substantial free cash flow ($730M TTM), funding a sustainable dividend (48.33% payout) and significant share buybacks ($301M in latest quarter). A high Return on Equity of 21.76% confirms efficient capital allocation.
- Healthy Balance Sheet: A strong current ratio of 3.88 and a manageable debt-to-equity ratio of 0.68 provide significant financial flexibility. This low leverage reduces risk and provides a buffer against economic downturns.
- Attractive Valuation After Sell-off: The forward P/E of 16.66x represents a significant compression from historical highs above 30x and is reasonable for a stable, profitable consumer staples company. The stock trades at 78% of its 52-week range, suggesting a potential value opportunity after a -15.46% annual decline.
Bearish
- Anemic Revenue Growth: Q3 FY2026 revenue grew only 2.71% YoY, a tepid pace for a premium brand owner. The multi-quarter trend shows a slow recovery from $894M in Q4 FY2025, raising concerns about the company's ability to reaccelerate top-line expansion.
- Severe Technical Downtrend: The stock has underperformed the S&P 500 by 46 percentage points over the past year (-15.46% vs. +30.59%). Despite a recent 20.52% monthly bounce, the price remains closer to its 52-week low ($22.61) than its high ($36.18), indicating persistent selling pressure.
- High Valuation Multiples: The Price/Sales ratio of 4.14x and Price/Book ratio of 4.12x are elevated, demanding stronger growth to justify. The Price/Cash Flow ratio of 27.54x is also high, indicating the market prices in significant future cash flow growth.
- Brand Concentration Risk: The company's fortunes are heavily tied to the Jack Daniel's brand within the Whiskey segment, which drove $797M of the latest quarter's $1.063B revenue. This concentration creates vulnerability to shifts in consumer preference or competitive pressures in the whiskey category.
BF-B Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -15.46%, significantly underperforming the broader market's 30.59% gain. Currently trading at $28.31, the price sits at approximately 78% of its 52-week range ($22.61 to $36.18), indicating it is closer to its lows than its highs, which may suggest a value opportunity but also reflects persistent selling pressure and negative sentiment. Recent momentum shows a sharp but volatile recovery, with a 1-month surge of 20.52% and a 3-month gain of 3.63%, which diverges strongly from the longer-term downtrend. This short-term rally, which includes a significant spike to $30.31 on April 9th, could signal a potential trend reversal or a bear market rally, but it follows a severe drawdown from the highs seen in late 2025. Key technical support is clearly defined at the 52-week low of $22.61, while resistance lies near the 52-week high of $36.18. A sustained breakout above the recent April high near $30.31 would be needed to signal a more durable recovery, while a breakdown below $22.61 would confirm the bearish trend's continuation. The stock's beta of 0.421 indicates it is significantly less volatile than the market, which is typical for a consumer defensive name but also suggests muted potential for explosive upside without a fundamental catalyst.
Beta
0.42
0.42x market volatility
Max Drawdown
-51.9%
Largest decline past year
52-Week Range
$23-$36
Price range past year
Annual Return
-25.2%
Cumulative gain past year
| Period | BF-B Return | S&P 500 |
|---|---|---|
| 1m | -6.9% | +12.6% |
| 3m | -6.7% | +2.5% |
| 6m | -7.1% | +4.3% |
| 1y | -25.2% | +28.4% |
| ytd | -4.0% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BF-B Fundamental Analysis
Revenue growth has been modest but positive, with the most recent Q3 FY2026 revenue of $1.063 billion representing a 2.71% year-over-year increase. The multi-quarter trend shows revenue has grown from $894 million in Q4 FY2025 to the current level, indicating a steady, albeit slow, recovery trajectory, with the Whiskey segment ($797 million in the latest period) remaining the dominant growth driver. The company is solidly profitable, with Q3 net income of $267 million and a robust gross margin of 60.87%. Margins have shown improvement sequentially, with the Q3 gross margin of 60.87% up from 59.56% in Q2 and 57.38% in Q4 FY2025, suggesting effective cost management and pricing power are supporting profitability despite revenue headwinds. The balance sheet is healthy, with a strong current ratio of 3.88 and a manageable debt-to-equity ratio of 0.68. The company generates substantial cash, with trailing twelve-month free cash flow of $730 million, providing ample liquidity to fund its dividend (payout ratio of 48.33%) and share repurchases, as evidenced by $301 million in buybacks in the latest quarter, while maintaining a respectable return on equity of 21.76%.
Quarterly Revenue
$1.1B
2026-01
Revenue YoY Growth
+0.02%
YoY Comparison
Gross Margin
+0.60%
Latest Quarter
Free Cash Flow
$730000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BF-B Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 18.95x, while the forward P/E is 16.66x, indicating the market expects modest earnings growth, as the forward multiple implies a slight discount to the current earnings stream. Compared to sector averages (data not available in the provided set), a direct peer comparison cannot be quantified, but the forward P/E in the mid-teens is typical for a mature, stable consumer staples company with moderate growth expectations. Historically, the stock's own trailing P/E has compressed significantly from levels above 30x seen in 2021-2022. The current P/E of 18.95x is below the peak historical multiples and sits near the middle of its recent historical range (from 12.09x in Q3 FY2026 to 28.20x in Q4 FY2025), suggesting the valuation has normalized and may not be demanding if earnings growth resumes.
PE
18.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 12x~80x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is anemic revenue growth of 2.71% YoY, which pressures a valuation reliant on premium multiples (PS 4.14x, P/CF 27.54x). While margins are expanding, the company faces concentration risk, with the Jack Daniel's-led Whiskey segment representing approximately 75% of latest quarterly revenue. Earnings visibility is reduced by the stock's high short ratio of 4.55, indicating significant investor skepticism about near-term prospects.
Market & Competitive Risks: The stock trades at a forward P/E of 16.66x, which, while below its own history, is not cheap for a company with single-digit revenue growth, creating valuation compression risk if growth disappoints. Its low beta of 0.421 offers defensive characteristics but also limits upside participation in broad market rallies. The consumer staples sector faces macro headwinds like inflation and shifting demand, which could further pressure volume growth for premium spirits.
Worst-Case Scenario: The most damaging scenario involves a continuation of the revenue slowdown coupled with margin pressure, triggering multiple compression. This could be exacerbated by a loss of market share for the flagship Jack Daniel's brand. Realistic downside could see the stock retest its 52-week low of $22.61, representing a potential loss of approximately -20% from the current price of $28.31. A breach of this level could trigger a move toward the stock's maximum historical drawdown of -51.89% from its peak, though that extreme scenario is less probable given the company's strong balance sheet.
FAQ
The key risks are, in order of severity: 1) Growth Risk: Anemic revenue growth (2.71% YoY) that fails to accelerate, leading to valuation compression. 2) Concentration Risk: Heavy reliance on the Jack Daniel's brand within the Whiskey segment, which comprises ~75% of quarterly revenue. 3) Valuation Risk: High absolute multiples (PS 4.14x) that are vulnerable if growth disappoints. 4) Sentiment Risk: A high short ratio of 4.55 reflects significant market skepticism, which can perpetuate selling pressure even if fundamentals are stable.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $28 and $32, assuming continued low-single-digit growth and stable margins. The Bull Case (25% probability) targets $33 to $36 on revenue reacceleration and multiple expansion. The Bear Case (15% probability) warns of a drop to $22-$26 if growth stalls and multiples contract. The Base Case is most likely, driven by the assumption that the company's strong profitability offsets its slow growth, resulting in modest price appreciation. The key variable is the trajectory of quarterly revenue growth.
BF-B is fairly valued relative to its current growth profile. Its forward P/E of 16.66x is reasonable for a stable consumer staples company but is not a deep discount. The Price/Sales ratio of 4.14x and Price/Cash Flow of 27.54x are elevated, indicating the market is still paying a premium for its brand strength and profitability. Compared to its own history, where the trailing P/E has compressed from over 30x, the valuation has normalized. The current multiple implies the market expects low-single-digit earnings growth, which aligns with recent results, suggesting the stock is neither significantly overvalued nor undervalued.
BF-B is a good buy for a specific type of investor: those seeking a stable, defensive holding with strong cash generation and a sustainable dividend, who are willing to accept modest growth. The stock offers a 2.55% dividend yield and is buying back shares aggressively. However, with only 2.71% revenue growth and a forward P/E of 16.66x, it lacks a compelling growth catalyst for near-term outperformance. It is not a good buy for growth-oriented investors. The biggest downside risk is a further de-rating if growth stagnates, with potential for a -20% decline to the 52-week low.
BF-B is unequivocally suited for long-term investment, with a suggested minimum holding period of 3-5 years. Its low beta (0.421) and defensive characteristics make it a poor candidate for short-term trading, as it lacks volatility for quick gains. As a long-term holding, investors can benefit from the compounding effect of its dividend (2.55% yield) and share repurchases, while allowing time for potential revenue growth to reaccelerate. The company's strong brand equity and cash-generative business model are tailwinds for patient capital, but short-term investors are likely to be disappointed by its sluggish price action.
